{
    "2018-02-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Roche Reports Positive Data From Tecentriq-Avastin Study",
                "features": {
                    "keywords": [
                        "Roche",
                        "Tecentriq-Avastin",
                        "Positive Data"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflows",
                        "VEA",
                        "NSRGY",
                        "NVS",
                        "TM"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "The Diseases We Aren’t Curing—And Why",
                "features": {
                    "keywords": [
                        "Diseases",
                        "Curing",
                        "Why"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-18",
                "original_text": "How Did Kalydeco Perform in 4Q17 and 2017?",
                "features": {
                    "keywords": [
                        "Kalydeco",
                        "Performance",
                        "4Q17",
                        "2017"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-19",
                "original_text": "Analysts’ Recommendations for Novartis after Its 4Q17 Earnings",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "Novartis",
                        "4Q17",
                        "Earnings"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "The Swiss Stock Market Sank Below The 9,000 Point Level",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Sank",
                        "9,000 Point Level"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-21",
                "original_text": "Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall",
                "features": {
                    "keywords": [
                        "Xtandi",
                        "AMAG",
                        "CORT",
                        "Fall"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            }
        ]
    ]
}